Tc-99m-annexin V-128

Drug Profile

Tc-99m-annexin V-128

Alternative Names: 99mTc-rhAnnexin V-128; 99mTechnetium-labelled rhAnnexin V-128; rhAnnexin V-128; Tc-99m-recombinant human annexin V-128; Tc-99m-rhAnnexin V-128

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Atreus Pharmaceuticals
  • Developer Advanced Accelerator Applications; INSERM
  • Class Calcium binding proteins; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cardiomyopathies; Carotid stenosis; Spondylarthritis
  • Phase I/II Ankylosing spondylitis; Cardiovascular disorders; Rheumatoid arthritis
  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis
  • 26 Oct 2017 Atreus Pharmaceuticals terminates a phase I/II trial in Ankylosing spondylitis and Rheumatoid arthritis (Diagnosis) in Switzerland due to low recruitment (IV) (NCT02328027)
  • 18 Sep 2017 Phase-II clinical trials in Spondylarthritis (Diagnosis) in USA (IV) (NCT03232580)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top